RxDoctor Payments Data

W Hendrix, MD

Internal Medicine · Richmond, VANPI 1477532893

Payments from drug & device makers

$4,151in general payments, 2019–2025

Across 255 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$709
  • Novo Nordisk$388
  • Pfizer$376
  • Lilly USA, LLC$294
  • Amgen$283
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$221
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$4,135100%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,151 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$228,312
Medicare patients
629
Services billed
3,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$164,512
JardianceEmpagliflozin62$53,783
XareltoRivaroxaban30$32,349
JanuviaSitagliptin Phosphate28$31,642
RybelsusSemaglutide15$23,359
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$11,764
SymbicortBudesonide/Formoterol Fumarate21$9,606
Colesevelam Hcl16$8,519
Humalog Kwikpen U-100Insulin Lispro31$7,947
TradjentaLinagliptin12$7,228
CelebrexCelecoxib22$7,165
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$5,851
Atorvastatin Calcium644$5,805
Potassium Chloride137$5,650
LexaproEscitalopram Oxalate12$5,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Celebrex$376$171,677205 claims
Boehringer IngelheimJardiance, Tradjenta$120$61,01174 claims
Johnson & JohnsonXarelto$24$32,34930 claims
MerckJanuvia$114$31,64228 claims
Novo NordiskRybelsus$388$23,35915 claims
AstraZenecaSymbicort$91$9,60621 claims
AbbVieLexapro, Synthroid$709$8,69380 claims
Sanofi-aventis U.S. LLCLantus$82$3,32117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →